

Agenda

MOC na ASCO 2023



TUMORES HEPATO-BILIO-PANCREÁTICOS



Ricardo Carvalho

- Oncologista clínico titular, com foco no tratamento de Tumores Gastrointestinais (esôfago, estômago, pâncreas, fígado, intestino) e Genito-urinários (próstata, bexiga e rim). Graduado na Universidade Federal de Pernambuco (UFPE) em 2004. Residência em Clínica Médica no Hospital Barão de Lucena (PE) em 2007. Residência em Oncologia Clínica no Hospital de Câncer de Barretos (SP) em 2010. Ex-assistente em Oncologia Clínica no Hospital Sírio Libanês. Membro da *American Society of Clinical Oncology (ASCO)*, *European Society for Medical Oncology (ESMO)*, Sociedade Brasileira de Oncologia Clínica (SBOC), *American Association for Clinical Research (AACR)* e Grupo Brasileiro de Tumores Gastrointestinais (GTG). Já publicou mais de 40 capítulos em livros nacionais e internacionais. Possui mais de 30 palestras em Congressos nacionais e internacionais.
- CRM 132.389.



Conflito de interesses

De acordo com a Norma 1595/2000 do Conselho Federal de Medicina e com a RDC 96/2008 da ANVISA, declaro que:

- *Speaker*: Merck, Roche, United Medical, AstraZeneca, MSD, BMS, Bayer, Lilly, Servier, Janssen e Astellas.
- *Advisory board*: United Medical, Servier, AstraZeneca, Merck e Lilly.
- Não possuo ações em quaisquer destas companhias farmacêuticas.

Tumores Hepato-bilio-pancreáticos



Oral abstract session

- 1. **Abstract #4002:** Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.

Presenter: Masatoshi Kudo, MD, PhD | Kindai University Hospital

- 2. **Abstract #4004:** Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).

Presenter: George Lau, MD | Humanity and Health Clinical Trial Center, Humanity and Health Medical Group

Tumores Hepato-bilio-pancreáticos



Oral abstract session

- 3. **LBA4005**: Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).

Presenter: Knut Jørgen Labori, MD PhD | Oslo University Hospital.

- 4. **Abstract #4006**: Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.

Presenter: Eileen Mary O'Reilly, MD | Memorial Sloan Kettering Cancer Center.

Tumores Hepato-bilio-pancreáticos



Oral abstract session

- 5. **Abstract #4003:** Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC).

Presenter: Changhoon Yoo, MD, PhD | Asan Medical Center, University of Ulsan College of Medicine

- 6. **Abstract #4007:** Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.

Presenter: Yoshiaki Nakamura, MD, PhD | National Cancer Center Hospital Japan East

- 7. **Abstract #4008:** Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).

Presenter: Shubham Pant, MD | MD Anderson Cancer Center



Outros estudos que merecem atenção

Poster Discussion Session

- 8. **Abstract #4015 (Poster #336):** Phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.

Presenter: Jieer Ying | Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

- 9. **Abstract #4016 (Poster #337):** A randomized study of consolidation chemoradiation (CTRT) vs observation after first-line chemotherapy (CT) in advanced gall bladder cancers (GBC): RACE-GB Study.

Presenter: Sushma Agrawal, MD | SGPGI

- 10. **Abstract #4017 (Poster #338):** A multicenter, open-label, randomized phase II study evaluating adjuvant gemcitabine plus cisplatin (GC) and capecitabine with concurrent capecitabine radiotherapy (CAPE-RT) in patients with operated gallbladder adenocarcinoma (GBC): The GECCOR-GB trial.

Presenter: Anant Ramaswamy, DM | Tata Memorial Hospital (HBNI)

Outros estudos que merecem atenção



MOC na ASCO 2023

Poster Discussion Session

- **11. Abstract #4021 (Poster #342): FOOTPATH:** A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).

- Presenter: Benedikt Westphalen, MD | Comprehensive Cancer Center, University Hospital Munich, Germany

- **12. Abstract #4023 (Poster #344):** Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial.

Presenter: Wei Wei, M.D, PH.D | Sun Yat-sen University Cancer Center

Créditos

MOC na ASCO 2023 © 2023 MOC - Manual de Oncologia Clínica do Brasil. Todos os direitos reservados. São Paulo, SP.
Proibida a reprodução total ou parcial do conteúdo e imagens sem a permissão dos titulares de seus direitos autorais.

Apoio educacional:

